These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

412 related articles for article (PubMed ID: 23440284)

  • 1. Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study.
    Singh S; Chang HY; Richards TM; Weiner JP; Clark JM; Segal JB
    JAMA Intern Med; 2013 Apr; 173(7):534-9. PubMed ID: 23440284
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies.
    Elashoff M; Matveyenko AV; Gier B; Elashoff R; Butler PC
    Gastroenterology; 2011 Jul; 141(1):150-6. PubMed ID: 21334333
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elevated amylase and lipase levels in patients using glucagonlike peptide-1 receptor agonists or dipeptidyl-peptidase-4 inhibitors in the outpatient setting.
    Lando HM; Alattar M; Dua AP
    Endocr Pract; 2012; 18(4):472-7. PubMed ID: 22440997
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Case report of acute necrotizing pancreatitis associated with combination treatment of sitagliptin and exenatide.
    Iyer SN; Drake AJ; West RL; Mendez CE; Tanenberg RJ
    Endocr Pract; 2012; 18(1):e10-3. PubMed ID: 22068258
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The potential risks of pancreatitis and pancreatic cancer with GLP-1-based therapies are far outweighed by the proven and potential (cardiovascular) benefits.
    Ryder RE
    Diabet Med; 2013 Oct; 30(10):1148-55. PubMed ID: 24073725
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glucagon-like peptide 1-based therapies and risk of pancreatitis: a self-controlled case series analysis.
    Li X; Zhang Z; Duke J
    Pharmacoepidemiol Drug Saf; 2014 Mar; 23(3):234-9. PubMed ID: 24741695
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide.
    Dore DD; Seeger JD; Arnold Chan K
    Curr Med Res Opin; 2009 Apr; 25(4):1019-27. PubMed ID: 19278373
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GLP-1-based therapies: the dilemma of uncertainty.
    Spranger J; Gundert-Remy U; Stammschulte T
    Gastroenterology; 2011 Jul; 141(1):20-3. PubMed ID: 21723985
    [No Abstract]   [Full Text] [Related]  

  • 9. Incretin-based therapy and risk of acute pancreatitis: a nationwide population-based case-control study.
    Thomsen RW; Pedersen L; Møller N; Kahlert J; Beck-Nielsen H; Sørensen HT
    Diabetes Care; 2015 Jun; 38(6):1089-98. PubMed ID: 25633664
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis.
    Engel SS; Williams-Herman DE; Golm GT; Clay RJ; Machotka SV; Kaufman KD; Goldstein BJ
    Int J Clin Pract; 2010 Jun; 64(7):984-90. PubMed ID: 20412332
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pancreatitis associated with incretin-based therapies.
    Iyer SN; Tanenberg RJ; Mendez CE; West RL; Drake AJ
    Diabetes Care; 2013 Apr; 36(4):e49. PubMed ID: 23520376
    [No Abstract]   [Full Text] [Related]  

  • 12. Acute pancreatitis in patients with type 2 diabetes mellitus treated with dipeptidyl peptidase-4 inhibitors: a population-based nested case-control study.
    Chou HC; Chen WW; Hsiao FY
    Drug Saf; 2014 Jul; 37(7):521-8. PubMed ID: 24859164
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exenatide and sitagliptin are not associated with increased risk of acute renal failure: a retrospective claims analysis.
    Pendergrass M; Fenton C; Haffner SM; Chen W
    Diabetes Obes Metab; 2012 Jul; 14(7):596-600. PubMed ID: 22268550
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin: a retrospective observational pharmacy claims analysis.
    Garg R; Chen W; Pendergrass M
    Diabetes Care; 2010 Nov; 33(11):2349-54. PubMed ID: 20682680
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Journal withdraws article after complaints from drug manufacturers.
    Hawkes N
    BMJ; 2011 Apr; 342():d2335. PubMed ID: 21482597
    [No Abstract]   [Full Text] [Related]  

  • 16. An analysis of characteristics of subjects examined for incretin effects on pancreatic pathology.
    Harja E; Lord J; Skyler JS
    Diabetes Technol Ther; 2013 Aug; 15(8):609-18. PubMed ID: 23927624
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pro- or anti-inflammatory properties of the adipokine dipeptidyl peptidase-4?
    Xu L; Spinas GA; Niessen M
    Gastroenterology; 2011 Dec; 141(6):e17. PubMed ID: 22036848
    [No Abstract]   [Full Text] [Related]  

  • 18. Exenatide therapy and the risk of pancreatitis and pancreatic cancer in a privately insured population.
    Romley JA; Goldman DP; Solomon M; McFadden D; Peters AL
    Diabetes Technol Ther; 2012 Oct; 14(10):904-11. PubMed ID: 22845701
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pancreatitis associated with the use of GLP-1 analogs and DPP-4 inhibitors: a case/non-case study from the French Pharmacovigilance Database.
    Faillie JL; Babai S; Crépin S; Bres V; Laroche ML; Le Louet H; Petit P; Montastruc JL; Hillaire-Buys D;
    Acta Diabetol; 2014; 51(3):491-7. PubMed ID: 24352344
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis.
    Deacon CF; Mannucci E; Ahrén B
    Diabetes Obes Metab; 2012 Aug; 14(8):762-7. PubMed ID: 22471248
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.